Hepadvax (hepatitis B vaccine)
/ Vaxine
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 23, 2025
HBV003: A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
(clinicaltrials.gov)
- P1/2 | N=40 | Not yet recruiting | Sponsor: Vaxine Pty Ltd | Trial completion date: Dec 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2025 ➔ Mar 2027
Trial completion date • Trial primary completion date • Hepatitis B • Infectious Disease • Inflammation
April 09, 2024
HBV003: A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
(clinicaltrials.gov)
- P1/2 | N=40 | Not yet recruiting | Sponsor: Vaxine Pty Ltd | Trial completion date: Dec 2025 ➔ Dec 2026
Trial completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation
March 31, 2023
HBV003: A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
(clinicaltrials.gov)
- P1/2 | N=40 | Not yet recruiting | Sponsor: Vaxine Pty Ltd | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025
Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation
March 09, 2022
HBV003: A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection
(clinicaltrials.gov)
- P1/2 | N=40 | Not yet recruiting | Sponsor: Vaxine Pty Ltd | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024
Trial completion date • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation
1 to 4
Of
4
Go to page
1